DMTTF News and Press, Small Pharma From 08/15/22

LONDON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that...

LONDON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that...

Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company...

Small Pharma ( OTCQB:DMTTF ) appoints Mr. George Tziras as CEO of the company succeeding founder Mr. Peter Rands, effective as of July 20, 2022. Mr. Peter Rands will take on the role of Chief Innovation & Intellectual Property Officer of the compan...

Building on strong foundations to take Small Pharma through development to commercial success Peter Rands to take on role as Chief Innovation & Intellectual Property Officer LONDON, July 18, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) ...

Small Pharma press release ( OTCQB:DMTTF ): Q1 Cash on hand as of May 31, 2022 was $32.0 million. Cash used in operating activities was $6.3 million for the three months ended May 31, 2022. For further details see: Small Pharma reports Q1 results

Progress continues apace with multiple trials expected to enter clinic later this year First US patent granted LONDON, July 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Phar...

LONDON, United Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, anno...

Small Pharma press release (OTCPK:DMTTF): FY GAAP EPS of -C$0.07. Cash on hand as of February 28, 2022 of $40.7 million. For further details see: Small Pharma GAAP EPS of -C$0.07

Reporting its financial results and continued p rogress across short-acting psychedelics portfolio Executive team and IP position strengthened LONDON, June 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Com...